Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aetna Seeks To Serve As National Rx Drug Plan Under Medicare Part D

This article was originally published in The Pink Sheet Daily

Executive Summary

The company is the first large health plan to announce its intent to market a national PDP directly to individual Medicare beneficiaries. Aetna Pharmacy Management, the insurer's in-house PBM, will administer the benefit.

You may also be interested in...



Aetna Members To Exclusively Use Specialty Pharmacy Joint Venture By October

The Aetna/Priority Healthcare joint venture’s Orlando, Fla. distribution center will begin servicing Aetna members in the first quarter. Aetna says it will switch all members who use specialty medicines from other distributors to Aetna Specialty Pharmacy by the end of the third quarter.

Ovations Seeks To Be National Medicare Drug Plan Sponsor

Insurer notifies CMS of its intent to offer a national prescription drug plan, making it the second large health plan after Aetna to disclose such an intent. Ovations’ parent company, UnitedHealth Group, is the largest health plan client of Medco, which has also applied to sponsor a PDP.

Aetna Members To Exclusively Use Specialty Pharmacy Joint Venture By October

The Aetna/Priority Healthcare joint venture’s Orlando, Fla. distribution center will begin servicing Aetna members in the first quarter. Aetna says it will switch all members who use specialty medicines from other distributors to Aetna Specialty Pharmacy by the end of the third quarter.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS061612

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel